Skip to main content
KYUNG NAM PHARM.CO.,LTD. logo

KYUNG NAM PHARM.CO.,LTD. — Investor Relations & Filings

Ticker · 053950 ISIN · KR7053950002 KO Manufacturing
Open in API
Filings indexed 437 across all filing types
Latest filing 2026-05-21 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 053950

About KYUNG NAM PHARM.CO.,LTD.

https://www.kyungnampharm.com:6519/eng/

Kyung Nam Pharm is a pharmaceutical company established in 1957 that specializes in over-the-counter (OTC) medicines and health functional foods. The company is widely known for its flagship brand, Lemona, which was the first powdered Vitamin C product in its domestic market and is now marketed as an inner-beauty product. The core product portfolio also includes PM, a topical treatment for athlete's foot, and Minol F Troche for sore throats. A key area of specialization is human placenta-based medicines; the company was a pioneer in developing and commercializing human placenta drink formulations. Kyung Nam Pharm focuses on developing accessible healthcare solutions based on its corporate philosophy of promoting human health.

Recent filings

Filing Released Lang Actions
증권신고서(지분증권)
Share Issue/Capital Change Classification · 90% confidence The document is a full-length “증권신고서(지분증권)”—a securities registration statement/prospectus for the issuance of 11,000,000 shares by 경남제약 주식회사, including detailed offering terms, risk factors, and use of proceeds. It is not merely an announcement or summary but the complete share issuance prospectus. This fits the ‘Share Issue/Capital Change’ category (SHA), which covers new share issues or other capital changes.
2026-05-21 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 93% confidence The document is a Korean major event report (“주요사항보고서”) announcing and detailing a paid-in capital increase (유상증자) via rights offering. It provides extensive terms for new share issuance, pricing, allocation, and subscription schedule. This matches the Share Issue/Capital Change category (SHA).
2026-05-21 Korean
주주명부폐쇄기간또는기준일설정
Share Issue/Capital Change Classification · 85% confidence The document is a formal announcement of the shareholder register closure period and record date in connection with a paid-in capital increase (rights issue) – detailing the record date, book closure dates, purpose (new share allocation), and board resolution date. This falls under announcements regarding new share issues/capital changes.
2026-05-21 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 94% confidence The document is a detailed Korean “대량보유상황보고서” – a large-shareholding report filed under the Capital Markets Act, including prior and current holdings, percentage changes, contracts, and acquisition funding. This clearly matches a Major Shareholding Notification.
2026-05-21 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence The document is titled “분기보고서 (제29기 1분기) 2026년 01월 01일~2026년 03월 31일” and contains detailed Q1 consolidated financial statements, operating and production data, capital changes, and narrative analysis for the first quarter of fiscal 2026. This matches the definition of an Interim/Quarterly Report (IR) with substantive financial data. Therefore, it should be classified as IR. Q1 2026
2026-05-15 Korean
[기재정정]주주총회소집결의 (임시주주총회)
Proxy Solicitation & Information Statement Classification · 78% confidence The document is a formal notice of the board resolution to convene an extraordinary general meeting (임시주주총회소집결의), including agenda details and proxy information. It is not the meeting minutes or voting results, nor a management discussion, but rather the solicitation materials for shareholders to prepare and vote. This matches the definition for Proxy Solicitation & Information Statement (PSI).
2026-05-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.